Amphastar Pharma (NASDAQ: AMPH) reported Q3 EPS of $0.10, $0.03 better than the analyst estimate of $0.07. Revenue for the quarter came in at $80.1 million versus the consensus estimate of $78.53 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.